Mucosal immune response in BNT162b2 COVID-19 vaccine recipients-Reference-Cited by-同舟云学术

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients

Published:2022-01 Issue: Volume:75 Page:103788
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Azzi Lorenzo^ORCID,Dalla Gasperina Daniela^ORCID,Veronesi Giovanni,Shallak Mariam,Ietto Giuseppe,Iovino Domenico,Baj Andreina,Gianfagna Francesco,Maurino Vittorio,Focosi Daniele^ORCID,Maggi Fabrizio,Ferrario Marco Mario,Dentali Francesco,Carcano Giulio,Tagliabue Angelo,Maffioli Lorenzo Stefano,Accolla Roberto Sergio,Forlani Greta

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference40 articles.

1. Coronavirus disease (COVID-19) dashboard,2021

2. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’;Lavezzo;Nature,2020

3. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2;Hodgson;Lancet Infect Dis,2021

4. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting;Dagan;N Engl J Med,2021

5. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review;Vaccine: X;2024-10

2. Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting;Vaccine;2024-10

3. Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters;Frontiers in Immunology;2024-08-30

4. COVID‐19 vaccine adverse events: Evaluating the pathophysiology with an emphasis on sulfur metabolism and endotheliopathy;European Journal of Clinical Investigation;2024-08-08

5. A Nasal Vaccine Candidate, Containing Three Antigenic Regions from SARS-CoV-2, to Induce a Broader Response;Vaccines;2024-05-28